Clomiphene citrate and gonadotropins are the two pillars of ovulation induction, but they work through fundamentally different mechanisms and carry different trade-offs in cost, convenience, risk, and pregnancy rates. Clomiphene is a pill taken for five days early in the menstrual cycle; gonadotropins are injectable hormones administered daily, often for a week or more, under close monitoring. Choosing between them, or combining them, depends on the diagnosis, how a patient has responded to prior treatment, and what level of complexity and expense is acceptable.
How They Work
Clomiphene citrate is a selective estrogen receptor modulator. It binds to estrogen receptors in the hypothalamus and blocks estrogen’s usual negative feedback signal, essentially tricking the brain into thinking estrogen levels are low. The hypothalamus responds by ramping up the pulsatile release of gonadotropin-releasing hormone, which in turn tells the pituitary gland to secrete more follicle-stimulating hormone (FSH) and luteinizing hormone (LH).1PubMed. Clomiphene citrate in the management of anovulation: a review of mechanisms, outcomes, and clinical challenges Early studies measuring LH pulses over eight-hour windows showed that clomiphene roughly doubled the pulse frequency within just a few days, confirming a hypothalamic site of action.2The Journal of Clinical Endocrinology & Metabolism. Evidence for a Hypothalamic Site of Action of Clomiphene Citrate in Women The body’s own pituitary then does the heavy lifting, producing FSH and LH in its normal pulsatile pattern but at higher levels.
Gonadotropins skip the brain entirely. These injectable preparations contain FSH, LH, or both, and they act directly on the ovaries. Because you are delivering the stimulating hormone rather than coaxing the body to make more of it, gonadotropins offer much finer control over the intensity of stimulation. They can recruit multiple follicles, which is why they are the backbone of in vitro fertilization (IVF) protocols. But that power comes with a steeper risk curve: more monitoring, more expense, and a higher chance of ovarian hyperstimulation syndrome and high-order multiple pregnancies.
Who Gets Clomiphene First
For most women who are not ovulating regularly, clomiphene is still the standard first-line treatment. It is inexpensive, taken orally, and effective enough to produce ovulation in a majority of cycles. In women with polycystic ovary syndrome (PCOS), the most common cause of anovulatory infertility, clomiphene produces ovulation in roughly half to two-thirds of treatment cycles.3PubMed Central. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial A large Cochrane review confirmed that clomiphene improves the chance of clinical pregnancy compared with placebo, though it also noted a reduced chance of live birth when compared directly with gonadotropins.4Cochrane Database of Systematic Reviews. Clomiphene and other antioestrogens for subfertility associated with anovulation
The typical starting dose is 50 mg daily for five days, beginning on day two to five of the cycle. If that does not trigger ovulation, the dose can be stepped up in 50 mg increments to a maximum of about 150 to 200 mg per day. Some evidence suggests that extending clomiphene to a ten-day course may modestly improve pregnancy outcomes compared with the standard five-day regimen, though the data are limited.5PubMed Central. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome
When Gonadotropins Take Over
Gonadotropins become the treatment of choice when clomiphene fails to produce ovulation or pregnancy after several cycles, when a woman’s hypothalamic-pituitary axis is not functioning (so there is nothing for clomiphene to amplify), or when the goal is controlled ovarian hyperstimulation for IVF. In clomiphene-resistant PCOS, switching to low-dose gonadotropin protocols can coax the ovaries into responding where clomiphene could not.
One cost-effective strategy for clomiphene-resistant women is to combine clomiphene with a low dose of injectable FSH rather than switching entirely to gonadotropins. In a randomized trial, women who took clomiphene alongside a small daily dose of urinary FSH ovulated at more than double the rate of women given the same low-dose FSH alone, and they used significantly less total FSH and needed fewer days of injections.6PubMed Central. Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial The pregnancy and live birth rates ended up similar between the two groups, but the combination approach was gentler and cheaper.
Clomiphene Versus Gonadotropins Head to Head
In direct comparisons for anovulatory infertility, gonadotropins tend to produce higher ovulation rates and somewhat higher live birth rates than clomiphene, but at substantially greater cost and complexity. A cost-effectiveness analysis from a Dutch randomized trial reported live birth rates of about 52% with gonadotropins versus 41% with clomiphene, with mean costs of roughly €4,500 per woman for gonadotropins and €3,000 for clomiphene.7Human Reproduction. Gonadotrophins versus clomiphene citrate with or without IUI in women with normogonadotropic anovulation and clomiphene failure: a cost-effectiveness analysis Each additional live birth gained by using gonadotropins instead of clomiphene cost an estimated €15,000 or more. Whether that trade-off is worth it depends on a family’s circumstances, insurance coverage, and how many treatment cycles they are willing to attempt.
For women over 35 or those with a poor response to standard IVF stimulation, some clinics use a combined protocol: clomiphene plus high-dose recombinant FSH along with a delayed gonadotropin-releasing hormone antagonist. This approach aims to squeeze more follicular development out of diminished ovarian reserves while keeping total gonadotropin use manageable.8PubMed. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years In IVF specifically, a Cochrane review found that adding clomiphene to gonadotropin protocols did not clearly improve live birth rates or ongoing pregnancy rates, but it did reduce the number of gonadotropin vials used and the number of eggs retrieved, and it lowered the incidence of ovarian hyperstimulation.9Cochrane Database of Systematic Reviews. Clomiphene citrate with or without gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization or intracytoplasmic sperm injection cycles The trade-off is a higher cycle cancellation rate, because the milder stimulation sometimes fails to produce enough follicles to proceed.
Where Letrozole Fits In
Letrozole, an aromatase inhibitor originally developed for breast cancer, has emerged as a serious competitor to clomiphene for first-line ovulation induction. A landmark trial published in the New England Journal of Medicine found that women with PCOS who received letrozole had a cumulative live birth rate of about 28%, compared with about 19% for clomiphene, and a higher cumulative ovulation rate as well.10PubMed Central. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome Letrozole also tends to produce single follicle development more often, which reduces the twin and triplet risk. Many fertility guidelines now list letrozole alongside or ahead of clomiphene as a first-line option for PCOS.
For women who fail clomiphene, letrozole and clomiphene-gonadotropin combinations are the main alternatives. In a large randomized comparison of clomiphene-resistant PCOS patients, letrozole alone achieved a pregnancy rate of about 23%, while the clomiphene-plus-gonadotropin combination reached roughly 18%, with the combination having a higher cycle cancellation rate.11PubMed Central. Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial
Clomiphene’s Effect on Cervical Mucus and the Uterine Lining
One well-known drawback of clomiphene is its anti-estrogen effect on tissues beyond the hypothalamus. Because clomiphene blocks estrogen receptors throughout the body, it can thin the cervical mucus and interfere with endometrial development, both of which matter for conception. Studies have consistently found that women taking clomiphene have lower cervical mucus scores than women on gonadotropins or in natural cycles.12PubMed. The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles Poor cervical mucus can physically impede sperm transport, potentially undermining the ovulation that the drug successfully triggered.
The endometrial picture is more nuanced. By day 20 of the cycle, the lining looks similar in clomiphene-treated and untreated women, but by day 24 there is a measurable delay in endometrial maturation.13PubMed. Clomiphene citrate affects cervical mucus and endometrial morphology independently of the changes in plasma hormonal levels induced by multiple follicular recruitment This is one reason clinicians sometimes add estrogen supplementation or switch patients who are not conceiving despite ovulating on clomiphene to gonadotropins or letrozole, both of which avoid this anti-estrogen side effect on reproductive tissues.
Safety and Risk of Ovarian Hyperstimulation
Ovarian hyperstimulation syndrome (OHSS) is the most feared short-term complication of ovulation induction. Mild forms cause bloating and pelvic discomfort; severe cases involve massive fluid shifts, blood clots, and kidney failure. Gonadotropins carry a much higher risk than clomiphene because they stimulate the ovaries more aggressively. A Cochrane analysis found that adding clomiphene or letrozole to IVF protocols in place of standard gonadotropin-heavy regimens reduced the incidence of OHSS from about 6% down to somewhere between 0.5% and 2.5%.14Cochrane Database of Systematic Reviews. Oral ovulation induction agents with or without gonadotropins versus gonadotropins-only regimens for controlled ovarian stimulation in IVF/ICSI cycles That said, clomiphene is not risk-free on this front. Rare case reports document severe OHSS and even ovarian torsion following clomiphene alone, so the possibility should not be dismissed entirely.15PubMed Central. Ovarian Hyperstimulation secondary to clomiphene citrate resulting in ovarian torsion: A rare report
Multiple pregnancy is the other major safety concern. Gonadotropins are the bigger culprit here. In a trial comparing letrozole, clomiphene, and gonadotropins for unexplained infertility, roughly a third of ongoing pregnancies in the gonadotropin group were multiples, including ten sets of triplets. Clomiphene and letrozole both produced far fewer multiples, mostly twins.16PubMed Central. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility Monitoring with ultrasound and estrogen levels during stimulation helps clinicians decide whether to proceed or cancel a cycle when too many follicles develop.17PubMed. Measurement of the ovarian follicle by ultrasound in ovulation induction
Triggering Ovulation After Stimulation
Once follicles reach maturity during a clomiphene or gonadotropin cycle, ovulation usually needs to be triggered. The traditional trigger is an injection of human chorionic gonadotropin (hCG), which mimics the natural LH surge. An alternative is a gonadotropin-releasing hormone agonist, which induces the body’s own LH and FSH surge. In clomiphene-stimulated cycles, a GnRH agonist trigger produced an LH surge in all patients tested, while hCG failed to produce a detectable surge in some women.18PubMed. Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist In women with PCOS, who are at elevated risk for OHSS, GnRH agonist triggers after clomiphene have shown promise as a safer alternative to hCG without compromising pregnancy rates across repeated cycles.19Middle East Fertility Society Journal. Triggering ovulation with gonadotropin-releasing hormone agonist versus human chorionic gonadotropin in polycystic ovarian syndrome
Long-Term Cancer Risk Concerns
Any drug that stimulates the ovaries raises questions about long-term cancer risk, and the data on this front are unsettling but far from definitive. The underlying problem in studying this is that infertility itself is a risk factor for ovarian cancer, and women who remain childless after treatment face the highest baseline risk. Disentangling the drug’s contribution from the disease’s contribution is difficult.
A 2025 meta-analysis found that women exposed to any ovarian-stimulating drugs had a modestly increased risk of both invasive ovarian cancer and borderline ovarian tumors compared to unexposed women, including unexposed infertile women. Combined treatment with clomiphene and gonadotropins was associated with an increased risk of borderline ovarian tumors specifically, and six or more gonadotropin cycles appeared to raise the risk of invasive ovarian cancer.20PubMed. Ovarian-stimulating drug use and risk of ovarian tumor in infertile women: a meta-analysis A large registry-based cohort study found that the ovarian cancer risk from clomiphene was concentrated among women who remained nulliparous after treatment, with about a two-and-a-half-fold increase compared to multiparous women.21Cancer Epidemiology, Biomarkers & Prevention. Cancer Risk in Women Treated with Fertility Drugs According to Parity Status—A Registry-based Cohort Study The same study found elevated endometrial cancer risk in clomiphene-treated women, with the highest risk in nulliparous women and in parous women who received more than six cycles.
A Cochrane review described the overall quality of this evidence as very low, largely because the available studies cannot fully separate the effects of the drugs from the effects of infertility and nulliparity themselves.22PubMed Central. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility In practical terms, these findings do not mean patients should avoid treatment, but they do inform how clinicians think about the number of treatment cycles and the transition from oral agents to gonadotropins. Most guidelines recommend limiting clomiphene use to around six ovulatory cycles before moving on to a different approach.
Clomiphene and Gonadotropins in Male Infertility
Clomiphene’s mechanism of blocking estrogen receptors and boosting gonadotropin output works in men too, which is why it is widely used off-label for male hypogonadism and infertility. In men with low testosterone, clomiphene raises testosterone levels by increasing the brain’s signal to the testes without shutting down sperm production, as exogenous testosterone replacement does.23PubMed. Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis A meta-analysis of clomiphene for male infertility found that about 60% of treated men showed improved sperm concentrations.24PubMed Central. Effectiveness of Clomiphene Citrate for Improving Sperm Concentration: A Literature Review and Meta-Analysis
Gonadotropins also play a role in male infertility, particularly in men whose pituitary gland does not produce enough FSH and LH on its own. In those cases, injections of FSH (to stimulate sperm production) and hCG (to substitute for LH and stimulate testosterone production) can restore fertility. This is a fundamentally different clinical scenario from the ovulation induction context in women: the gonadotropins here are replacing a missing signal rather than amplifying a sluggish one.
Off-Label Use After Anabolic Steroids
A less discussed but increasingly common use of clomiphene is as part of “post-cycle therapy” among men who have used anabolic steroids. Anabolic steroids suppress the hypothalamic-pituitary-testicular axis, and when a user stops taking them, testosterone production can remain suppressed for weeks or months. Clomiphene is used to speed recovery by blocking the estrogen receptors in the hypothalamus, thereby increasing gonadotropin secretion and stimulating the testes to resume natural testosterone production.25PubMed. Clomiphene Citrate in off-Label Post-Cycle Therapy: Mechanisms, Efficacy and Diagnostic Challenges in Endocrine Recovery Following Anabolic Steroid Use This application complicates anti-doping testing, since standard immunoassays used to monitor hormonal recovery have limited specificity. Mass spectrometry provides more reliable results but is not always used in routine clinical settings.
Cost and Treatment Burden
The financial and logistical gap between clomiphene and gonadotropins is enormous. A course of clomiphene tablets costs relatively little and requires minimal monitoring in straightforward cases, often just one or two ultrasounds per cycle. Gonadotropin cycles involve daily injections, frequent blood draws and ultrasounds, and medication costs that can run into the thousands per cycle. A study comparing a clomiphene-gonadotropin cotreatment protocol to a standard gonadotropin-heavy IVF protocol in women over 35 found that the cotreatment group spent about 21% less per patient.26PubMed Central. The cumulative live birth rate and cost-effectiveness of the clomiphene and gonadotropin cotreatment protocol versus the mid-luteal GnRH agonist protocol in women over 35 years old
Beyond cost, the treatment experience differs sharply. Clomiphene is a pill. It is associated with hot flashes, mood swings, and visual disturbances in some patients, but the regimen is simple. Gonadotropins require self-administered injections, often daily for ten or more days, and the monitoring schedule means frequent clinic visits. For many patients, the physical and emotional toll of gonadotropin cycles is significantly higher. This is one reason clinicians generally exhaust simpler options before escalating, and why combination protocols that use clomiphene to reduce the total dose and duration of injectable gonadotropins are appealing even when they do not improve pregnancy rates outright.
Clomiphene Resistance and What Comes After It
About 15 to 25% of women with PCOS do not ovulate even on maximum-dose clomiphene, a situation called clomiphene resistance. There are several strategies before jumping straight to full-dose gonadotropins. One Japanese study found that an intermittent clomiphene regimen, cycling on and off the medication, restored ovulation in about 80% of clomiphene-resistant PCOS patients.27PubMed Central. Usefulness of intermittent clomiphene citrate treatment for women with polycystic ovarian syndrome that is resistant to standard clomiphene citrate treatment The Cochrane review also found limited evidence that adding dexamethasone or a combined oral contraceptive pretreatment to clomiphene may help, though the data were too uncertain to draw firm conclusions.28PubMed Central. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome
For women who ovulate on clomiphene but do not conceive after several cycles, a different problem may be at play. The anti-estrogen effects on the cervical mucus and endometrium described earlier can create a hostile environment for conception even when the egg is released on schedule. In these cases, switching to letrozole or gonadotropins, or combining clomiphene with intrauterine insemination to bypass the cervical mucus issue, are common next steps.
Pharmacogenomics and Why Responses Vary
Researchers have tried to understand why some women respond well to clomiphene while others do not, looking at genetic variations in the enzymes that metabolize the drug. One candidate was the CYP2D6 gene, which is known to affect how the body processes many common medications. A study measuring clomiphene and its metabolite levels in patients with different CYP2D6 genotypes confirmed that drug levels varied with ovulation status, but the CYP2D6 variants themselves did not explain the differences in drug response.29PubMed Central. Genetic Polymorphism of CYP2D6 and Clomiphene Concentrations in Infertile Patients with Ovulatory Dysfunction Treated with Clomiphene Citrate This means that, at least for now, there is no genetic test that reliably predicts who will respond to clomiphene and who will need gonadotropins from the start. Clinicians still rely on clinical features like body mass index, anti-Müllerian hormone levels, and ovarian antral follicle counts to guide their initial treatment choices.